Selected research
Market Structure
Global Atazanavir Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Atazanavir market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Atazanavir is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Atazanavir is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Atazanavir is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Atazanavir is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Atazanavir include TEVA, Mylan, Emcure, Cipla, Bristol-Myers Squibb and Aurobindo Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Atazanavir market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Atazanavir and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Atazanavir sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Atazanavir market size, projected growth trends, production technologies, key applications, and end-use industries.
Atazanavir Segment by Company
TEVA
Mylan
Emcure
Cipla
Bristol-Myers Squibb
Aurobindo Pharma
Atazanavir Segment by Type
50 mg Oral Powder
300 mg Capsule
200 mg Capsule
150 mg Capsule
Atazanavir Segment by Application
Adults
Children 3 months of age and older
Atazanavir Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Atazanavir market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Atazanavir and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Atazanavir.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Atazanavir market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Atazanavir manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Atazanavir in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Atazanavir in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- 50 mg Oral Powder
- 300 mg Capsule
- 200 mg Capsule
- 150 mg Capsule
Applications
- Adults
- Children 3 months of age and older
Companies covered
- TEVA
- Mylan
- Emcure
- Cipla
- Bristol-Myers Squibb
- Aurobindo Pharma
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Atazanavir Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Atazanavir Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Atazanavir Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Atazanavir Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Atazanavir Market Dynamics
- 2.1 Atazanavir Industry Trends
- 2.2 Atazanavir Industry Drivers
- 2.3 Atazanavir Industry Opportunities and Challenges
- 2.4 Atazanavir Industry Restraints
3 Atazanavir Market by Manufacturers
- 3.1 Global Atazanavir Revenue by Manufacturers (2021-2026)
- 3.2 Global Atazanavir Sales by Manufacturers (2021-2026)
- 3.3 Global Atazanavir Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Atazanavir Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Atazanavir Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Atazanavir Manufacturers, Product Type & Application
- 3.7 Global Atazanavir Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Atazanavir Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Atazanavir Players Market Share by Revenue in 2025
- 3.8.3 2025 Atazanavir Tier 1, Tier 2, and Tier 3
4 Atazanavir Market by Type
- 4.1 Atazanavir Type Introduction
- 4.1.1 50 mg Oral Powder
- 4.1.2 300 mg Capsule
- 4.1.3 200 mg Capsule
- 4.1.4 150 mg Capsule
- 4.2 Global Atazanavir Sales by Type
- 4.2.1 Global Atazanavir Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Atazanavir Sales by Type (2021-2032)
- 4.2.3 Global Atazanavir Sales Market Share by Type (2021-2032)
- 4.3 Global Atazanavir Revenue by Type
- 4.3.1 Global Atazanavir Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Atazanavir Revenue by Type (2021-2032)
- 4.3.3 Global Atazanavir Revenue Market Share by Type (2021-2032)
5 Atazanavir Market by Application
- 5.1 Atazanavir Application Introduction
- 5.1.1 Adults
- 5.1.2 Children 3 months of age and older
- 5.2 Global Atazanavir Sales by Application
- 5.2.1 Global Atazanavir Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Atazanavir Sales by Application (2021-2032)
- 5.2.3 Global Atazanavir Sales Market Share by Application (2021-2032)
- 5.3 Global Atazanavir Revenue by Application
- 5.3.1 Global Atazanavir Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Atazanavir Revenue by Application (2021-2032)
- 5.3.3 Global Atazanavir Revenue Market Share by Application (2021-2032)
6 Global Atazanavir Sales by Region
- 6.1 Global Atazanavir Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Atazanavir Sales by Region (2021-2032)
- 6.2.1 Global Atazanavir Sales by Region (2021-2026)
- 6.2.2 Global Atazanavir Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Atazanavir Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Atazanavir Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Atazanavir Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Atazanavir Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Atazanavir Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Atazanavir Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Atazanavir Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Atazanavir Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Atazanavir Revenue by Region
- 7.1 Global Atazanavir Revenue by Region
- 7.1.1 Global Atazanavir Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Atazanavir Revenue by Region (2021-2026)
- 7.1.3 Global Atazanavir Revenue by Region (2027-2032)
- 7.1.4 Global Atazanavir Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Atazanavir Revenue (2021-2032)
- 7.2.2 North America Atazanavir Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Atazanavir Revenue (2021-2032)
- 7.3.2 Europe Atazanavir Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Atazanavir Revenue (2021-2032)
- 7.4.2 Asia-Pacific Atazanavir Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Atazanavir Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Atazanavir Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 TEVA
- 8.1.1 TEVA Company Information
- 8.1.2 TEVA Business Overview
- 8.1.3 TEVA Atazanavir Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 TEVA Atazanavir Product Portfolio
- 8.1.5 TEVA Recent Developments
- 8.2 Mylan
- 8.2.1 Mylan Company Information
- 8.2.2 Mylan Business Overview
- 8.2.3 Mylan Atazanavir Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Mylan Atazanavir Product Portfolio
- 8.2.5 Mylan Recent Developments
- 8.3 Emcure
- 8.3.1 Emcure Company Information
- 8.3.2 Emcure Business Overview
- 8.3.3 Emcure Atazanavir Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Emcure Atazanavir Product Portfolio
- 8.3.5 Emcure Recent Developments
- 8.4 Cipla
- 8.4.1 Cipla Company Information
- 8.4.2 Cipla Business Overview
- 8.4.3 Cipla Atazanavir Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Cipla Atazanavir Product Portfolio
- 8.4.5 Cipla Recent Developments
- 8.5 Bristol-Myers Squibb
- 8.5.1 Bristol-Myers Squibb Company Information
- 8.5.2 Bristol-Myers Squibb Business Overview
- 8.5.3 Bristol-Myers Squibb Atazanavir Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Bristol-Myers Squibb Atazanavir Product Portfolio
- 8.5.5 Bristol-Myers Squibb Recent Developments
- 8.6 Aurobindo Pharma
- 8.6.1 Aurobindo Pharma Company Information
- 8.6.2 Aurobindo Pharma Business Overview
- 8.6.3 Aurobindo Pharma Atazanavir Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Aurobindo Pharma Atazanavir Product Portfolio
- 8.6.5 Aurobindo Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Atazanavir Value Chain Analysis
- 9.1.1 Atazanavir Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Atazanavir Production Mode & Process
- 9.2 Atazanavir Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Atazanavir Distributors
- 9.2.3 Atazanavir Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst